Drugs / ASP3082
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07483983 | Mar 2026 → Sep 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-14 | Astellas Pharma Inc | Astellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinoma astellas.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP3082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483983 ↗ |
| Route | Intravenous | “ASP3082 will be administred in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal.” NCT07483983 ↗ |